Matching articles for "nogapendekin alfa inbakicept"
Issue 1740 · October 27, 2025
Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)

The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or…

Med Lett Drugs Ther. 2025 Oct 27; 67(1740):e176-7 doi:10.58347/tml.2025.1740c
The FDA has approved Inlexzo , a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ , with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.
Issue 1705 · June 24, 2024 Free
In Brief: Anktiva for Bladder Cancer (online only)

Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of…

Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e105-6 doi:10.58347/tml.2024.1705e
Nogapendekin alfa inbakicept-pmln ( Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin) and the immune checkpoint inhibitor pembrolizumab (Keytruda) are also approved for the same indication.